« Previous | Next » | All Messages |  IAGX Message Board Home | recommend post |  Ignore Poster

IAGX News Imagenetix to Market Branded Joint Health Formula to Pro Sports Teams and Universities Nationwide

SAN DIEGO--(BUSINESS WIRE)--Imagenetix, Inc. (OTCBB: IAGX) today announced that, effectively immediately, it will market its branded joint health formula to professional sports teams and leading universities nationwide.

The product, Inflame Away™ With Celadrin® Sport, will be offered in a 32-ounce pump topical formula, as well as in a 90-count bottle oral formula.

Spearheading the Inflame Away™ With Celadrin® Sport sales program will be renowned athletic coach Charley Baker. Mr. Baker has coached such notables as former NBA star and 1984 Olympic Gold Medalist Joe Kleine, Utah Jazz guard Derek Fisher, former NBA player and coach Darrell Walker, Sacramento Kings forward Corliss Williamson, and double Olympic Gold Medalist in the 400 and 1600 meter relay, Lee Evans.

Mr. Baker has also been a track and field coach at Indiana University as well as a head referee and official at major track events across the nation.

“I cannot imagine a single professional sports team or university that would not benefit by carrying Inflame Away™ With Celadrin® Sport,” said Mr. Baker. “With its clinically proven ability to create rapid and significant enhancement of joint health, this product should help athletes maximize the time they can remain on the field and perform with comfort and efficiency.”

Imagenetix president William P. Spencer added, “We are thrilled to begin selling this, our first branded product, directly to pro teams and universities. This strategy, led by Charley Baker, has real potential to produce a lucrative revenue stream for our company.”

With his appointment, Charley Baker joins four other Olympians with Imagenetix: Ken Cole, Derek Boosey, Barry King and Yueling Chen.

Today’s news follows up Imagenetix’ recent announcement of a nationwide branding program for Inflame Away™ With Celadrin® to leading mass-market retailers nationwide.

Celadrin®, the primary ingredient of Inflame Away™, has been shown to provide rapid and significant enhancement of joint health(1), with no reported side effects, in double-blind, placebo-controlled trials published in peer-reviewed medical journals. Regarding Celadrin® topical formula, the April 2004 Journal of Rheumatology reported that 100 percent of arthritic subjects experienced less pain and greater range of motion within 30 minutes of applying the product. A second topical study, in the February 2005 Journal of Strength & Conditioning Research, found that knee arthritic participants had 43 percent less pain and improved posture within one week of application.

A Celadrin® oral study, published in the February 2002 Journal of Rheumatology, reported that subjects experienced significant improvement in joint flexibility, the ability to walk up and down stairs and the ability to walk extended distances, within 30 days of commencing consumption of the product.(1)

Fifteen other scientific studies have validated Celadrin®’s safety and/or efficacy.

San Diego-based Imagenetix, Inc., www.imagenetix.net, is developing novel pharmaceuticals for the treatment of inflammatory diseases. The company also develops and markets natural-based proprietary products, including over-the-counter topical creams and skin care products, for inflammation-related markets.

(1) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Safe Harbor Statement This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company expects to file with the Securities Exchange Commission.